CervoMed
Develops neflamapimod for age-related brain disorders.
Something off on this page? Send us feedback.
Profile
Develops neflamapimod, an investigational oral small molecule, for dementia with Lewy bodies and other age-related brain disorders. The clinical-stage business is organized around this single lead candidate, including manufacturing work intended to improve drug concentrations.
Develops neflamapimod, an investigational oral small molecule designed to cross the blood–brain barrier and selectively inhibit p38α. Its clinical programs span dementia with Lewy bodies, non-fluent variant primary progressive aphasia, recovery after ischemic stroke, and amyotrophic lateral sclerosis.
Operations are concentrated in the United States, with a small internal team supported by outside consultants and contractors. The company’s work centers on advancing a single lead candidate through clinical development rather than selling commercial products.
RewinD-LB’s randomized phase did not show significant differences on its primary or secondary outcomes. Subsequent exploratory work examined a newer drug batch after the company identified a drug-substance property and implemented a manufacturing improvement. Clinical results remain investigational rather than regulatory evidence of safety or efficacy.
Company facts
Key statistics
Year to date −66.6% · Average volume (30d) 336.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Roth Capital | Target | $9 | $7 | ||
| May 18, 2026 | Roth Capital | Target | $20 | $9 | ||
| Nov 5, 2025 | H.C. Wainwright | Target | $25 | |||
| Nov 5, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy | ||
| Oct 17, 2025 | Roth Capital | Target | $16 | $20 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.80 | −$0.64 | +19.7% | $50.0K | — | — | −0.35% |
| Aug 7, 2026Q2 FY26 | −$0.87 | −$0.64 | +26.4% | $50.0K | — | — | +3.99% |
| May 18, 2026Q1 FY26 | −$0.90 | −$0.86 | +4.4% | $71.4K | — | — | −4.93% |
| Mar 13, 2026Q4 FY25 | −$0.79 | −$0.88 | −11.4% | $90.8K | $6.5K | −92.8% | +1.41% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $322.6K | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $322.6K | $0 | $0 | $0 | |
| Operating income | −$5.3M | −$6.6M | −$8.0M | −$8.3M | −$8.1M | −$6.7M | |
| Net income | −$4.9M | −$6.3M | −$7.7M | −$8.1M | −$8.0M | −$6.6M | |
| Diluted EPS | −$0.56 | −$0.70 | −$0.84 | −$0.87 | −$0.86 | −$0.64 | |
| Gross margin | — | — | 100.0% | — | — | — | |
| Operating margin | — | — | -2,493.8% | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $322.6K
Balance sheet, Jun 30, 2026Cash & short-term investments $24.9M · Total debt $0 · Total assets $26.0M · Shareholders' equity $23.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 9.26M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Joshua S. Boger · director, 10 percent owner: | 1.80M | 19.40% | Form 4 | Jun 15, 2026 |
| Armistice Capital, LLC | 1.59M | 9.53% | 13G | Aug 14, 2026 |
| John J. Alam · director, 10 percent owner, officer: CEO & President | 1.50M | 16.16% | Form 4 | Nov 19, 2025 |
| Sylvie Gregoire · director, 10 percent owner: | 1.50M | 16.16% | Form 4 | Nov 19, 2025 |
| RA Capital Management, L.P. | 1.03M | 9.90% | 13G | Aug 20, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 11, 2026 | Joshua S. Boger | director, 10 percent owner: | +2,866,242 | $3.20 |
| Nov 17, 2025 | John J. Alam | director, 10 percent owner, officer: CEO & President | +21,600 | $8.46 |
| Nov 17, 2025 | William Robert Elder | officer: CFO, GC & Secretary | +1,000 | $8.45 |
| Nov 18, 2025 | William Robert Elder | officer: CFO, GC & Secretary | +2,500 | $8.32 |
| Nov 17, 2025 | Sylvie Gregoire | director, 10 percent owner: | +21,600 | $8.46 |
Peers
- Cognition Therapeutics
DLB-psychosis pipeline with a once-daily oral therapy
- Coya Therapeutics
FTD and ALS pipeline built around COYA 302
- Ionis Pharmaceuticals
Targeted FUS-ALS therapy in a Phase 3 study
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CervoMed | $2.56 | −1.54% | $24.1M | — | — | 74.6 | −99.7% |
| Cognition Therapeutics | $1.04 | +1.99% | $91.3M | — | — | — | — |
| Coya Therapeutics | $4.57 | −0.52% | $107.7M | — | — | 13.4 | +35.6% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Median | — | — | 12.5 | −2.6% |